These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 8941871)

  • 1. Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts.
    Conlon KC; Anver MR; Longo DL; Ortaldo JR; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):317-23. PubMed ID: 8941871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
    Schmid I; Baldwin GC; Jacobs EL; Isacescu V; Neagos N; Giorgi JV; Glaspy JA
    Cytometry; 1995 Jun; 22(2):103-10. PubMed ID: 7587740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
    Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB
    Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in SCID mice.
    Chakraborty NG; Okino T; Stabach P; Padula SJ; Yamase H; Morse E; Sha'afi RI; Twardzik DR; Shultz LJ; Mukherji B
    In Vivo; 1991; 5(6):609-14. PubMed ID: 1810447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human RANTES induces the migration of human T lymphocytes into the peripheral tissues of mice with severe combined immune deficiency.
    Murphy WJ; Taub DD; Anver M; Conlon K; Oppenheim JJ; Kelvin DJ; Longo DL
    Eur J Immunol; 1994 Aug; 24(8):1823-7. PubMed ID: 7519996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
    Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
    Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
    Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
    Qi CF; Nieroda C; De Filippi R; Greiner JW; Correale P; Schlom J; Tsang KY
    Immunol Lett; 1995; 47(1-2):15-24. PubMed ID: 8537095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-gamma.
    Lei H; Ju DW; Yu Y; Tao Q; Chen G; Gu S; Hamada H; Cao X
    Gene Ther; 2000 Apr; 7(8):707-13. PubMed ID: 10800095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
    Vadhan-Raj S; Cordon-Cardo C; Carswell E; Mintzer D; Dantis L; Duteau C; Templeton MA; Oettgen HF; Old LJ; Houghton AN
    J Clin Oncol; 1988 Oct; 6(10):1636-48. PubMed ID: 3171629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimetastatic effect of recombinant human macrophage-colony-stimulating factor against lung and liver metastatic B16 melanoma.
    Sakurai T; Yamada M; Simamura S; Motoyoshi K
    Cancer Immunol Immunother; 1997 Mar; 44(1):48-54. PubMed ID: 9111584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
    Chapman PB; Gillies SD; Houghton AN; Reilly RM
    Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
    Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
    Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
    Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
    Bock SN; Cameron RB; Kragel P; Mulé JJ; Rosenberg SA
    Cancer Res; 1991 May; 51(10):2649-54. PubMed ID: 2021943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
    Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.